T1	Participants 273 314	German-Speaking Myeloma Multicenter Group
T2	Participants 612 649	314 of 604 patients had been enrolled
T3	Participants 663 726	598 patients who received at least one dose of trial medication
T4	Participants 776 820	patients treated with intravenous bortezomib
T5	Participants 1079 1127	patients treated intravenously or subcutaneously
